Cacciò SM et al. 2016. Multilocus sequence typing of Dientamoeba fragilis identified a major clone with widespread geographical distribution. Int J Parasitol 46: 793–798.
Norberg A, Nord CE, Evengard B, 2003. Dientamoeba fragilis a protozoan infection which may cause severe bowel distress. Clin Microbiol Infect 9: 65–68.
Stark D, García LS, Barratt JL, Phillips O, Roberts T, Marriott D, Harkness J, Ellis JT, 2014. Description of Dientamoeba fragilis cyst and precystic forms from human samples. J Clin Microbiol 52: 2680–2683.
Windsor JJ, Johnson EH, 1998. Dientamoeba fragilis: the unflagelated flagellate. Br J Biomed Sci 55: 172–175.
Johnson EH, Windsor JJ, Clark C, 2004. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 17: 553–570.
Stark D, Barratt J, Chan D, Ellis JT, 2016. Dientamoeba fragilis, the neglected trichomonad of the human bowel. Clin Microbiol Rev 29: 553–580.
Ockert G, Schmidt T, 1976. Evidence of Dientamoeba fragilis in Enterobius eggs using isoelectric point determination. J Hyg Epidemiol Microbiol Immunol 20: 76–81.
Boga JA, Rojo S, Fernández J, Rodríguez M, Iglesias C, Martínez-Camblor P, Vázquez F, Rodríguez-Guardado A, 2016. Is the treatment of Enterobius vermicularis co-infection necessary to eradicate Dientamoeba fragilis infection? Int J Infect Dis 49: 59–61.
Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J, 2010. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 82: 614–619.
Stark D, Beebe N, Marriott D, Ellis J, Harkness J, 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 43: 2718–2723.
Munasinghe VS, Vella GN, Ellis JT, Windsor PA, Stark D, 2013. Cyst formation and faecal–oral transmission of Dientamoeba fragilis–the missing link in the life cycle of an emerging pathogen. Int J Parasitol 43: 879–883.
Holtman GA, Kranenberg JJ, Blanker MH, Ott A, Lisman-van Leeuwen Y, Berger MY, 2017. Dientamoeba fragilis colonization is not associated with gastrointestinal symptoms in children at primary care level. Fam Pract 34: 25–29.
Nagata N, Marriott D, Harkness J, Ellis JT, Stark D, 2012. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist 2: 204–215.
Garcia LS, 2016. Dientamoeba fragilis, one of the neglected intestinal protozoa. J Clin Microbiol 54: 2243–2250.
Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P, 2012. Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. Am J Trop Med Hyg 87: 1046–1052.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 980 | 804 | 261 |
Full Text Views | 743 | 18 | 6 |
PDF Downloads | 285 | 11 | 2 |
Dientamoeba fragilis is an intestinal protozoan, usually considered nonpathogenic. However, in the last years, there has been an attempt to clarify its possible pathogenic role. We aim to evaluate the clinical and epidemiological characteristics of D. fragilis–infected patients. Adults with D. fragilis detection in feces who attended the Vall d’Hebron University Hospital (Barcelona, Spain) were evaluated retrospectively from April 2009 to March 2014. We classified the patients in asymptomatic, symptomatic without other causes except infection of D. fragilis, and symptomatic with another cause. Among symptomatic patients, treatment response was evaluated. One hundred eight patients were included. Sixty-three percent of the patients were immigrants, 29.6% were autochthonous, and 7.4% were travelers. Forty-nine (45.3%) patients presented symptoms, and eosinophilia was observed in 26 (24.1%) patients. Overall, 59 (54.7%) patients were asymptomatic, 15 (13.8%) presented symptoms which were attributable to other causes, and 34 (31.5%) patients presented symptoms with no other causes. In this last group, 29 patients received specific treatment and 65.5% of them presented a complete resolution of the symptoms. The group of symptomatic patients with no other cause had more proportion of women, more proportion of autochthonous people, and were older compared with the group of asymptomatic patients. Dientamoeba fragilis infection should be considered as pathogenic when other causes are ruled out.
Authors’ addresses: Lucía Miguel, Fernando Salvador, Adrián Sánchez-Montalvá, Daniel Molina-Morant, and Israel Molina, Department of Infectious Diseases, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain, E-mails: lucy_zgz86@hotmail.com, fmsalvad@vhebron.net, adsanche@vhebron.net, dani.molina7@gmail.com, and imolina@vhebron.net. Elena Sulleiro and Isabel López, Department of Microbiology, Vall d’Hebron University Hospital, PROSICS Barcelona, Barcelona, Spain, E-mails: esulleir@vhebron.net and maibel56@gmail.com.
Cacciò SM et al. 2016. Multilocus sequence typing of Dientamoeba fragilis identified a major clone with widespread geographical distribution. Int J Parasitol 46: 793–798.
Norberg A, Nord CE, Evengard B, 2003. Dientamoeba fragilis a protozoan infection which may cause severe bowel distress. Clin Microbiol Infect 9: 65–68.
Stark D, García LS, Barratt JL, Phillips O, Roberts T, Marriott D, Harkness J, Ellis JT, 2014. Description of Dientamoeba fragilis cyst and precystic forms from human samples. J Clin Microbiol 52: 2680–2683.
Windsor JJ, Johnson EH, 1998. Dientamoeba fragilis: the unflagelated flagellate. Br J Biomed Sci 55: 172–175.
Johnson EH, Windsor JJ, Clark C, 2004. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin Microbiol Rev 17: 553–570.
Stark D, Barratt J, Chan D, Ellis JT, 2016. Dientamoeba fragilis, the neglected trichomonad of the human bowel. Clin Microbiol Rev 29: 553–580.
Ockert G, Schmidt T, 1976. Evidence of Dientamoeba fragilis in Enterobius eggs using isoelectric point determination. J Hyg Epidemiol Microbiol Immunol 20: 76–81.
Boga JA, Rojo S, Fernández J, Rodríguez M, Iglesias C, Martínez-Camblor P, Vázquez F, Rodríguez-Guardado A, 2016. Is the treatment of Enterobius vermicularis co-infection necessary to eradicate Dientamoeba fragilis infection? Int J Infect Dis 49: 59–61.
Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J, 2010. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 82: 614–619.
Stark D, Beebe N, Marriott D, Ellis J, Harkness J, 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 43: 2718–2723.
Munasinghe VS, Vella GN, Ellis JT, Windsor PA, Stark D, 2013. Cyst formation and faecal–oral transmission of Dientamoeba fragilis–the missing link in the life cycle of an emerging pathogen. Int J Parasitol 43: 879–883.
Holtman GA, Kranenberg JJ, Blanker MH, Ott A, Lisman-van Leeuwen Y, Berger MY, 2017. Dientamoeba fragilis colonization is not associated with gastrointestinal symptoms in children at primary care level. Fam Pract 34: 25–29.
Nagata N, Marriott D, Harkness J, Ellis JT, Stark D, 2012. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist 2: 204–215.
Garcia LS, 2016. Dientamoeba fragilis, one of the neglected intestinal protozoa. J Clin Microbiol 54: 2243–2250.
Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P, 2012. Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. Am J Trop Med Hyg 87: 1046–1052.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 980 | 804 | 261 |
Full Text Views | 743 | 18 | 6 |
PDF Downloads | 285 | 11 | 2 |